These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38779335)

  • 1. Impact of Pre-existing Type 2 Diabetes Mellitus and Cardiovascular Disease on Healthcare Resource Utilization and Costs in Patients With COVID-19.
    Nguyen C; Crowe CL; Kuti E; Donato B; Djaraher R; Seman L; Graeter N; Power TP; Mehra R; Willey VJ
    J Health Econ Outcomes Res; 2024; 11(1):112-121. PubMed ID: 38779335
    [No Abstract]   [Full Text] [Related]  

  • 2. Differences in All-Cause Health Care Utilization and Costs in a Type 2 Diabetes Mellitus Population with and Without a History of Cardiovascular Disease.
    Mehta S; Ghosh S; Sander S; Kuti E; Mountford WK
    J Manag Care Spec Pharm; 2018 Mar; 24(3):280-290. PubMed ID: 29485954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of cardiovascular disease on health care economic burden and resource utilization: a retrospective cohort study in adults in the United States with type 2 diabetes with or without stroke, myocardial infarction, and peripheral arterial disease.
    King A; Rajpura J; Liang Y; Paprocki Y; Uzoigwe C
    Curr Med Res Opin; 2022 Nov; 38(11):1831-1840. PubMed ID: 36134459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost of cardiovascular diseases and renal complications in people with type 2 diabetes mellitus in the Kingdom of Saudi Arabia: A retrospective analysis of claims database.
    Al-Jedai AH; Almudaiheem HY; Alissa DA; Al-Enazy HS; Korayem GB; Alghamdi A; Alghamdi S
    PLoS One; 2022; 17(10):e0273836. PubMed ID: 36264903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Healthcare Costs and Resource Utilization Associated with the Use of Empagliflozin Versus Other Antihyperglycemic Agents Among Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease: A Real-World Retrospective Cohort Analysis.
    Raju A; Pimple P; Stafkey-Mailey D; Farrelly E; Shetty S
    Diabetes Ther; 2022 Jan; 13(1):25-42. PubMed ID: 34727356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fracture risk and healthcare resource utilization and costs among osteoporosis patients with type 2 diabetes mellitus and without diabetes mellitus in Japan: retrospective analysis of a hospital claims database.
    Sato M; Ye W; Sugihara T; Isaka Y
    BMC Musculoskelet Disord; 2016 Nov; 17(1):489. PubMed ID: 27887655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing risk of future cardiovascular events, healthcare resource utilization and costs in patients with type 2 diabetes, prior cardiovascular disease and both.
    Nguyen C; Luthra R; Kuti E; Willey VJ
    Curr Med Res Opin; 2020 Dec; 36(12):1927-1938. PubMed ID: 33023310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Weight Change on Economic Outcomes Among Persons with Type 2 Diabetes Mellitus in the United States: Beyond Glycemic Control.
    Karkare S; Fridman M; Dang-Tan T; Lu J; Smolarz BG; DeKoven M; Iyer NN
    J Manag Care Spec Pharm; 2019 Jun; 25(6):658-668. PubMed ID: 30730232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Descriptive study of the economic burden among patients with type 2 diabetes mellitus, chronic kidney disease, and chronic kidney disease and type 2 diabetes mellitus in a large US commercially insured population.
    Chung H; Crowe CL; Kong SX; Singh R; Farej R; Elliott J; Williamson T; Willey VJ
    J Manag Care Spec Pharm; 2023 Jan; 29(1):80-89. PubMed ID: 36580126
    [No Abstract]   [Full Text] [Related]  

  • 10. Healthcare resource utilization and costs 2 years pre- and post-lumbar spine surgery for stenosis: a national claims cohort study of 22,182 cases.
    Koltsov JCB; Sambare TD; Alamin TF; Wood KB; Cheng I; Hu SS
    Spine J; 2022 Jun; 22(6):965-974. PubMed ID: 35123048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-existing cardiovascular diseases and glycemic control in patients with type 2 diabetes mellitus in Europe: a matched cohort study.
    Fu AZ; Qiu Y; Radican L; Yin DD; Mavros P
    Cardiovasc Diabetol; 2010 Apr; 9():15. PubMed ID: 20409333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Healthcare resource utilization and cost among patients with type 1 diabetes in the United States.
    Simeone JC; Shah S; Ganz ML; Sullivan S; Koralova A; LeGrand J; Bushman J
    J Manag Care Spec Pharm; 2020 Nov; 26(11):1399-1410. PubMed ID: 33119443
    [No Abstract]   [Full Text] [Related]  

  • 13. Health Care Resource Utilization and Costs Among Newly Diagnosed and Oral Anticoagulant-Naive Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran or Warfarin in the United States.
    Jain R; Fu AC; Lim J; Wang C; Elder J; Sander SD; Tan H
    J Manag Care Spec Pharm; 2018 Jan; 24(1):73-82. PubMed ID: 29290177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cost of cardiovascular-disease-related death in patients with type 2 diabetes mellitus.
    Shetty S; Stafkey-Mailey D; Yue B; Coutinho AD; Wang W; Del Parigi A; Sander SD; Coleman CI
    Curr Med Res Opin; 2018 Jun; 34(6):1081-1087. PubMed ID: 29480076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic burden and secondary complications of influenza-related hospitalization among adults in the US: a retrospective cohort study.
    Hu T; Miles AC; Pond T; Boikos C; Maleki F; Alfred T; Lopez SMC; McGrath L
    J Med Econ; 2024; 27(1):324-336. PubMed ID: 38343288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistence with Basal-Bolus Insulin Therapy in Patients with Type 2 Diabetes Mellitus and Effect on Clinical and Economic Outcomes: A Retrospective Claims Database Study.
    Edelman SV; Ermakova A; Xiong Y; Sieradzan R; Taylor SD
    J Manag Care Spec Pharm; 2019 Dec; 25(12):1420-1431. PubMed ID: 31550190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular and renal disease manifestation and healthcare resource utilization in patients on first-line oral therapy for type 2 diabetes: A claims-based observational cohort study.
    Olufade T; Jiang L; Israni R; Huang J; Gosmanov AR
    Diabetes Obes Metab; 2021 Dec; 23(12):2741-2751. PubMed ID: 34405521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of pre-existing type 2 diabetes with and without cardiovascular disease on patients with COVID-19.
    Nguyen C; Crowe CL; Kuti E; Narsipur N; Donato B; Pepe RS; Djaraher R; Seman L; Graeter N; Power TP; Mehra R; Willey VJ
    Diabetes Obes Metab; 2023 Sep; 25(9):2464-2472. PubMed ID: 36999236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retrospective database analysis of the impact of prior authorization for type 2 diabetes medications on health care costs in a Medicare Advantage Prescription Drug Plan population.
    Bergeson JG; Worley K; Louder A; Ward M; Graham J
    J Manag Care Pharm; 2013 Jun; 19(5):374-84. PubMed ID: 23697475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health care resource utilization and direct costs incurred over 24 months after initiating galcanezumab or standard-of-care preventive migraine treatments in the United States.
    Varnado OJ; Vu M; Buysman E; Kim G; Allenback G; Hoyt M; Trenz H; Cao F; Viktrup L
    J Manag Care Spec Pharm; 2024 Aug; 30(8):792-804. PubMed ID: 39088336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.